Sign in

    Canaccord Genuity Analyst • Canaccord Genuity Group Inc.

    Alif Kanji is an Investment Banking M&A Senior Analyst at Canaccord Genuity, specializing in merger and acquisition deal execution and client advisory for companies seeking to acquire, be acquired, or raise capital. He joined Canaccord Genuity after gaining prior experience at State Street Global Advisors in ETF financial sales, displaying a strong commitment to developing advanced analytical skills for investment banking. Kanji is known for supporting transaction processes through detailed financial analysis and client presentations, and began his career after earning his degree from the College of the Holy Cross in 2018, joining Canaccord Genuity after a formative stint at SSGA. He is expected to hold relevant FINRA securities licenses standard for U.S. investment banking analysts.

    Canaccord Genuity Analyst's questions to Rani Therapeutics Holdings Inc (RANI) leadership

    Canaccord Genuity Analyst's questions to Rani Therapeutics Holdings Inc (RANI) leadership • Q4 2024

    Question

    An analyst from Canaccord Genuity asked if Rani Therapeutics plans to conduct additional animal studies for the RT-114 program before advancing to clinical trials and questioned the company's confidence that human data will successfully replicate the promising preclinical results.

    Answer

    Executive Talat Imran confirmed that no further preclinical work is planned before moving RT-114 into the clinic. He expressed high confidence in the program's potential, citing the strong preclinical PK and weight loss data and the consistent bioavailability shown in the company's three previous Phase 1 studies, while noting the clinical trial will be the ultimate validation.

    Ask Fintool Equity Research AI